Derio, June 16, 2026

Resolutions Adopted at the Ordinary General Shareholders' Meetingin June 2026

We hereby report that the Ordinary General Shareholders' Meeting of ONCOMATRYX BIOPHARMA, S.A. was held on first call on June 16, 2026, at 12:30 p.m. at the Company's registered office, located at Parque Tecnológico de Bizkaia, Building 801b, Derio, Bizkaia, with shareholders attending both in person and remotely. Shareholders representing 94.22% of the voting share capital were present or represented.

All resolutions included on the agenda were unanimously approved, with the following breakdown:

- In favor: 100%
- Against: 0%
- Abstentions: 0%

The resolutions set forth on the agenda were approved, relating to:

- Approval of the Company's individual and consolidated annual financial statements for the fiscal year ended December 31, 2025.
- Approval of the Company's management for the fiscal year ended December 31, 2025.
- Allocation of the Company's net income for the fiscal year ended December 31, 2025.
- Approval of the maximum compensation for the CEO.
- Determination of the CEO's fixed compensation.
- Delegation of powers.
- Drafting, reading, and approval of the minutes of the meeting.

In Derio, on June 16, 2026

Mr. Laureano Simón Buela

CEO, Oncomatryx Biopharma, S.A.